Pete Lambert
Director, Program Management of the Inhaled Oxytocin Project, Monash University

Every year, over 300,000 women die during pregnancy and childbirth with postpartum haemorrhage (PPH), a condition of excessive blood loss after childbirth, being the leading cause. Although PPH can be effectively prevented or treated with an injection of oxytocin, access to this drug is limited due to the requirements for refrigeration, storage and trained medical personnel for administration. Pete Lambert and a team at Monash Institute of Pharmaceutical Sciences, led by Associate Professor Michelle McIntosh, are working on a project to develop a novel aerosol delivery system for oxytocin that can be inhaled by patients from a simple, disposable device immediately after childbirth. With no requirement for cold chain storage, this approach will increase access to this life saving commodity in resource-poor settings, where a large number of women give birth outside medical facilities or in understaffed and ill-equipped clinics with limited or no refrigeration facilities. Mr. Lambert is a UK registered pharmacist with over 20 years’ experience in drug development in the pharmaceutical industry. After an early career in large multinational pharma companies, Pete joined Britannia Pharmaceuticals, initially as a project manager developing a novel dry powder platform technology for nasal delivery, progressing to the role of Director of Development with responsibility for a broad development portfolio. On leaving Britannia in 2009, he volunteered in South Africa leading medical assistance projects in HIV/AIDS-affected communities in Kwa-Zulu Natal. This transformative experience led Pete to direct his expertise towards global health. Pete worked as the Director of Development at Medicines Development for Global Health prior to joining the inhaled oxytocin project team in June 2012. Pete received his MPhil in HIV/AIDS Management from Stellenbosch University in 2014